MENINGOCOCCAL POLYSACCHARIDE CONJUGATE INJ,LYPHL
Clinical Criteria Summary
Indication & Population
- Active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y
- Individuals 10 through 25 years of age
Administration & Dosing
- Injectable suspension for intramuscular use
- Single dose after reconstitution of the Lyophilized MenACWY Component with the MenB Component (approximately 0.5 mL)
- Administered according to a 0, 6-month schedule
Contraindications
- Severe allergic reaction (e.g., anaphylaxis) to any other diphtheria toxoid-containing vaccine
Warnings & Precautions
- Management of allergic reactions
- Syncope
- Limitation of vaccine effectiveness
- Altered immunocompetence
- Guillian-Barre syndrome
Clinical Guidance & Place in Therapy
- May be used when both MenACWY and MenB are indicated at the same visit
- Healthy persons aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine
- Persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia)